Caisse DE Depot ET Placement DU Quebec trimmed its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 12.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 345,900 shares of the company’s stock after selling 48,300 shares during the period. Caisse DE Depot ET Placement DU Quebec’s holdings in Eli Lilly and were worth $29,215,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Gradient Investments LLC acquired a new stake in shares of Eli Lilly and during the fourth quarter valued at approximately $103,000. Acrospire Investment Management LLC boosted its holdings in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and in the 2nd quarter valued at $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and in the 2nd quarter valued at $129,000. Finally, Front Row Advisors LLC bought a new stake in Eli Lilly and in the 4th quarter valued at $137,000. Hedge funds and other institutional investors own 77.58% of the company’s stock.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of the company’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $76.50, for a total value of $65,790.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.12, for a total value of $780,780.00. Following the completion of the transaction, the senior vice president now directly owns 152,120 shares of the company’s stock, valued at approximately $12,339,974.40. The disclosure for this sale can be found here. Insiders have sold 12,261 shares of company stock worth $987,485 over the last 90 days. 0.20% of the stock is currently owned by corporate insiders.
A number of brokerages have commented on LLY. Goldman Sachs Group lowered shares of Eli Lilly and from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday, January 16th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 12th. Finally, Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $93.47.
Shares of Eli Lilly and Co (LLY) traded down $0.66 during trading on Wednesday, reaching $78.49. The company’s stock had a trading volume of 2,931,977 shares, compared to its average volume of 5,015,698. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. The stock has a market cap of $86,596.06, a PE ratio of -393.28, a P/E/G ratio of 1.47 and a beta of 0.28. Eli Lilly and Co has a 1-year low of $73.69 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. During the same period in the previous year, the firm earned $0.95 earnings per share. The business’s revenue was up 7.0% compared to the same quarter last year. sell-side analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Caisse DE Depot ET Placement DU Quebec Lowers Holdings in Eli Lilly and Co (NYSE:LLY)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/03/14/eli-lilly-and-co-lly-shares-sold-by-caisse-de-depot-et-placement-du-quebec.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.